scholarly journals Feasibility Study of Autologous Peripheral Blood Stem Cell Transplantation for the Treatment of Childhood Acute Myelogenous Leukemia

2000 ◽  
Vol 30 (3) ◽  
pp. 137-145 ◽  
Author(s):  
Y. Horikoshi
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Feasibility Study ◽  
Peripheral Blood ◽  
Acute Myelogenous Leukemia ◽  
Peripheral Blood Stem Cell ◽  
Myelogenous Leukemia ◽  
Acute Myelogenous ◽  
Blood Stem Cell Transplantation

scholarly journals ID3012 Evaluation of HLA-identical sibling allogenic peripheral blood stem cell transplantation for acute myelogenous leukemia at BTH, Vietnam

2017 ◽  
Vol 4 (S) ◽  
pp. 24
Author(s):  
Man Van Huynh
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Myelogenous Leukemia ◽  
Graft Versus Host ◽  
Acute Myelogenous ◽  
Blood Stem Cell Transplantation

Background: the purposes of this study were to assess the efficacy of HLA-identical sibling allogenic peripheral blood stem cell transplantation in the treatment for acute myelogenous leukemia (AML) at Blood transfusion and hematology hospital at Ho Chi Minh city.   Methods: retrospective study, case series.   Results: from June 2005 to September 2016, there were 47 AML patients included 24 males and 23 females, with median age was 36 years old. Engraftment was achieved in 47 patients (100%). The median number of transfused CD34+ cells was 7.5 x 106/kg. The median time for neutrophil engraftment and platelet engraftment were 11 ± 2.8 days and 12.5 ± 10.1 days respectively. Oral mucositis occurred in 38 patients (80.9%), febrile neutropenia in 42 patients (89.4%), acute graft-versus-host disease (aGvHD) in 14 patients (29.8%), chronic graft-versus-host disease (cGvHD) in 10 patients (21.3%), and VOD in 6 patients (12.8%). Transplant-related mortality (TRM) was 4 patients (8.5%). Median follow-up time was 52.26 months. Patients remained alive were 27 (57.4%). The 5-year overall survival (OS) and disease-free survival (DFS) were 55% and 54% respectively.   Conclusion: HLA-identical sibling allogeneic blood stem cell transplantation can reconstruct hematopoiesis quickly and is a favorable therapeutic method for AML patients. Further development and improvement of hematopoietic stem cell transplantation techniques along with graduated and individualized therapy are expected to provide better outcomes and improved quality of life for AML patients.

Sign in / Sign up

Export Citation Format

Share Document